Clinical Trial Update: A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety [Phase 3]

View source ↗

Summary

Phase III clinical study assessing SYN023 for rabies has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mononegavirales Infections
• Rabies
• Rhabdoviridae Infections
• Rna Virus Infections
• Virus Diseases

Drugs mentioned

• SYN023 (SYN023)

Snippet

Sponsor: Synermore Biologics (Suzhou) Co., Ltd. | Conditions: Rabies, Communicable Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-04-21